GGiantBullStocks

Definium Therapeutics, Inc. - Common Shares (DFTX)

NASDAQ · Healthcare

$42.80-3.36%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$4.85B
P/E ratio
EPS
Volume
1,221,632
52-week high
52-week low
Open
$43.85
Day high
$45.31
Day low
$42.75

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025-$183.79M-$2.06
2024-$108.68M-$1.54
2023-$95.73M-$2.44
2022-$56.8M-$1.84
2021-$93.04M-$3.40

About Definium Therapeutics, Inc. - Common Shares

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

CEO
Robert Barrow
Employees
74
Country
US
IPO date
Nov 15, 2016

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Definium Therapeutics, Inc. - Common Shares's stock price today?
DFTX is trading at $42.80 as of Jul 20, 2026.
What is Definium Therapeutics, Inc. - Common Shares's market cap?
Definium Therapeutics, Inc. - Common Shares (DFTX) has a market capitalization of $4.85B.
Does Definium Therapeutics, Inc. - Common Shares pay a dividend?
Definium Therapeutics, Inc. - Common Shares did not pay a dividend in its most recent reported fiscal year.
What sector is Definium Therapeutics, Inc. - Common Shares in?
Definium Therapeutics, Inc. - Common Shares operates in the Healthcare sector.